Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19, is ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

If we assume Moderna only hits the low end of its 2025 revenue forecast, the stock trades at roughly 9 times forward sales. That's well above the 7.2 price-to-sales ratio for the biotech industry.

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. Watch these crucial price levels.

and Moderna's share price sank nearly 17%. The conventional investing wisdom is that you shouldn't "try to catch a falling knife." Moderna's stock chart certainly looks like a falling knife.